The global pharmaceutical glass packaging market is projected to grow from USD 5.32 billion in 2025 to USD 12.39 billion by 2035, with a CAGR of 8.82%. Growth is driven by rising demand for injectables, biologics, and GLP-1 therapies, alongside stringent EU regulatory requirements for sustainability and anti-counterfeiting measures. Europe, particularly Germany, is expected to be a major growth contributor.

The European market for glass prefilled syringes and glass vials packaging equipment is projected to grow from USD 283.30 billion in 2025 to USD 389.13 billion by 2034, driven by rising demand for injectable biologics, sterile drug delivery systems, and advanced healthcare infrastructure.

The global prefilled syringes market is expanding, driven by the rising prevalence of chronic illnesses, greater use of biologics and biosimilars, and a growing trend toward self-injection. The market is expected to reach USD 28 billion by 2032, with North America leading the growth.

The global dual chamber prefilled syringes market is expected to grow at a CAGR of 9.0% from 2024 to 2034, driven by the increased demand for biologics and biosimilars. The market is projected to reach a valuation of US$ 5,495.5 million by 2034.

USNA vs. STVN: Which Stock Is the Better Value Option?

USNA vs. STVN: Which Stock Is the Better Value Option?

Fusion Pharmaceuticals (FUSN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TAK vs. STVN: Which Stock Is the Better Value Option?

Shares of HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results. HighPeak Energy posted GAAP earnings of 66 cents per share, versus market estimates of 65 cents per share. The company’s quarterly sales came in at $301.153 million versus expectations of $339.525 million. HighPeak Energy shares declined 15.3% to $13.49 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Lytus Technologies Holdings PTV. Ltd. (NASDAQ: LYT) shares jumped 404% to $11.65 after the company announced the launch of Lytus Cloud. CERo Therapeutics Holdings, Inc. (NASDAQ: CERO) gained 167% to $6.81. CERo Therapeutics announced the publication in clinical cancer research a paper titled "Therapeutic Targeting of TIM-4-L With Engineered T CellsFor Acute Myeloid Leukemia." Brera Holdings PLC (NASDAQ: BREA) shares climbed 97.5% to $2.0150 after the company announced that its Executive Chairman, Daniel McClory, acquired a majority stake in the company. Grom Social Enterprises, Inc. (NASDAQ: GROM) gained 88.3% to $1.45. The company announced that it entered into a non-binding letter of intent to acquire Arctic7. Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) rose 43% to $6.83. Creative Medical Technology announces FDA authorization for groundbreaking Type 1 diabetes prevention therapy under expanded access. Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) gained 40.5% to $8.35 after the company received FDA Breakthrough Therapy Designation for its MM120 program in generalized anxiety disorder. The company also announced 12-week durability data from its Phase 2B study of MM120. ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) jumped 34.2% to $2.1601 after the company announced that its subsidiary BioStrand developed a Foundation AI Model that uses Large Language Models Stacking and HYFT Technology. Beneficient (NASDAQ: BENF) shares rose 28.7% to $0.1287. Beneficient agreed to the financing of liquidity transactions for three separate funds managed by ff Venture Capital. MoneyLion Inc. (NYSE: ML) gained 28.3% to $67.43 ...

Stevanato (STVN) delivered earnings and revenue surprises of 0% and 3.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

TAK vs. STVN: Which Stock Is the Better Value Option?